First description of bacteremia caused by Oscillibacter valericigenes in a patient hospitalized for leg amputation.


Journal

Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 13 01 2020
revised: 07 07 2020
accepted: 15 07 2020
pubmed: 28 7 2020
medline: 9 6 2021
entrez: 27 7 2020
Statut: ppublish

Résumé

Initially isolated from the alimentary canal of a Japanese corbicula clam, Oscillibacter valericigenes is a Gram-negative rod, of which culture remains very difficult. Herein we present the first case of bacteremia due to Oscillibacter valericigenes, in humans. A 55-year-old man was hospitalized for clinical management of multiple neglected leg wounds (colonized with maggots) that had occurred during a motorcycle accident. Following radiological confirmation of the bone infection, a transfemoral amputation was performed to limit the risk of extended infection. During hospitalization, before the amputation, the patient experienced fever, biological inflammation justifying the sampling of multiple blood cultures. Anaerobic blood culture was positive after 34 hours, without identification by routine procedure (MALDI-TOF), justifying identification by 16S DNA sequencing. In the absence of possible subculture, antibiotic sensitivity testing could not be performed. A pre-emptive treatment by piperacillin-tazobactam was introduced for 14 days. The evolution was good, except for a local disunion. Complete phylogenic analysis of the clinical strain showed that it significantly differed from the reference strain, which is distantly related to the Clostridia cluster IV. Due to the culture conditions and specialized identification method by sequencing, prevalence of O. valericigenes may be underestimated. Optimization of blood culture procedures and utilization of 16S rRNA gene sequencing are tools needed for identification of rare pathogens that could help to optimize clinical management of infected patients.

Identifiants

pubmed: 32712374
pii: S1075-9964(20)30100-1
doi: 10.1016/j.anaerobe.2020.102244
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
DNA, Bacterial 0
RNA, Ribosomal, 16S 0
Piperacillin, Tazobactam Drug Combination 157044-21-8

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102244

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lauranne Broutin (L)

University Hospital of Poitiers, Bacteriology and Infection Control Laboratory, Infectious Agents Department, Poitiers, France.

Luc Deroche (L)

University Hospital of Poitiers, Bacteriology and Infection Control Laboratory, Infectious Agents Department, Poitiers, France.

Anthony Michaud (A)

University Hospital of Poitiers, Bacteriology and Infection Control Laboratory, Infectious Agents Department, Poitiers, France.

Gwenaël Le Moal (G)

University Hospital of Poitiers, Department of Infectious Diseases, CHU, Poitiers, France.

Christophe Burucoa (C)

University Hospital of Poitiers, Bacteriology and Infection Control Laboratory, Infectious Agents Department, Poitiers, France.

Louis-Etienne Gayet (LE)

University Hospital of Poitiers, Department of Orthopedic Surgery and Traumatology, CHU, Poitiers, France.

Chloé Plouzeau (C)

University Hospital of Poitiers, Bacteriology and Infection Control Laboratory, Infectious Agents Department, Poitiers, France.

Maxime Pichon (M)

University Hospital of Poitiers, Bacteriology and Infection Control Laboratory, Infectious Agents Department, Poitiers, France. Electronic address: maxime.pichon@chu-poitiers.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH